Pluri Inc., a forward-thinking biotechnology firm, has recently announced a groundbreaking collaborative project with Bar-Ilan University’s Research and Development Company (BIRAD). This innovative endeavor aims to develop cutting-edge allogeneic cell therapies specifically targeting solid tumors, a
Neurogene, a trailblazer in the gene therapy field concentrating on rare neurological diseases, has successfully clinched $200 million through a private funding deal designed to extend its financial runway until late 2027. This financing structure, recognized as a PIPE financing (Private Investment
The Global Plasma Protein Therapeutics Market is on a significant growth trajectory, projected to reach approximately USD 40 billion by 2030. This expansion is driven by the indispensable role that plasma protein therapies play in treating a wide array of medical conditions, such as hemophilia,
Monte Rosa Therapeutics, Inc., and Novartis have recently entered into an exclusive global development and commercialization license agreement that aims to advance molecular glue degraders (MGDs), with a particular focus on MRT-6160. This agreement grants Novartis the worldwide rights to develop,
Switzerland has established itself as a global leader in the biotech industry, making significant advancements in areas such as cancer treatment, immunotherapy, gene and cell therapy, and more. With a strong focus on personalized and precision medicine, the Swiss biotech sector thrives on
Rentschler Biopharma, a globally recognized Contract Development and Manufacturing Organization (CDMO), is making significant strides in the biomanufacturing landscape. The company's recent investments showcase its commitment to expanding cGMP capabilities and bolstering cell and gene therapy
